Jeong Il Yu1, Doo Ho Choi2, Seung Jae Huh1, Sung Ja Ahn3, Ji Shin Lee4, Kyung Hwan Shin5, Youngmee Kwon5, Yong Bae Kim6, Chang-Ok Suh6, Jin Hee Kim7, Jihyoung Cho8, In Ah Kim9, Jong Hoon Lee10, Won Park1. 1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: doho.choi@samsung.com. 3. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea. 4. Department of Pathology, Chonnam National University Medical School, Gwangju, Korea. 5. Research Institute and Hospital, National Cancer Center, Goyang, Korea. 6. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. 7. Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. 8. Department of Surgery, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. 9. Department of Radiation Oncology, Seoul National University Bundang Hospital, Gyeonggi, Korea. 10. Department of Radiation Oncology, St Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.
Abstract
BACKGROUND: This retrospective study was performed to investigate the need for management modification in MBC according to evaluation of characteristics and failure patterns compared with IDC. PATIENTS AND METHODS: We performed this multicenter study taking MBC and randomly assigned IDC cases matched for age (± 3 years), pathologic stage (T and N), locoregional treatment methods (surgery with or without radiation therapy), and period of treatment (± 6 months) that occurred from January 1999 to November 2011 in the 6 institutions of the Korean Radiation Oncology Group. RESULTS: A total of 144 female MBC patients were enrolled. The median follow-up was 51 months (range, 1-186 months). The rates of positivity for estrogen receptor (P < .001), progesterone receptor (P < .001), and HER2 (P = .007) were significantly lower in MBC patients. During follow-up, recurrence developed in 22 (15.3%) MBC and 6 (4.2%) IDC patients (P = .002). The median time to recurrence of MBC and IDC was 15 months and 24 months, respectively. Most instances of recurrence in MBC developed in the triple-negative (TN) subgroup (TN-MBC). In particular, locoregional recurrence developed exclusively in the TN-MBC subgroup. In the TN-MBC subgroup, the number of risk factors (pT2-3, N1-3) was related to significant differences in overall survival (P = .001) and recurrence-free survival (P < .001). CONCLUSION: The MBC patients had a higher rate of TN, poorer differentiation, and a higher recurrence rate than did the IDC patients. Considering the unique characteristics and failure patterns, it is necessary to modify the current management guidelines for MBC.
BACKGROUND: This retrospective study was performed to investigate the need for management modification in MBC according to evaluation of characteristics and failure patterns compared with IDC. PATIENTS AND METHODS: We performed this multicenter study taking MBC and randomly assigned IDC cases matched for age (± 3 years), pathologic stage (T and N), locoregional treatment methods (surgery with or without radiation therapy), and period of treatment (± 6 months) that occurred from January 1999 to November 2011 in the 6 institutions of the Korean Radiation Oncology Group. RESULTS: A total of 144 female MBCpatients were enrolled. The median follow-up was 51 months (range, 1-186 months). The rates of positivity for estrogen receptor (P < .001), progesterone receptor (P < .001), and HER2 (P = .007) were significantly lower in MBCpatients. During follow-up, recurrence developed in 22 (15.3%) MBC and 6 (4.2%) IDC patients (P = .002). The median time to recurrence of MBC and IDC was 15 months and 24 months, respectively. Most instances of recurrence in MBC developed in the triple-negative (TN) subgroup (TN-MBC). In particular, locoregional recurrence developed exclusively in the TN-MBC subgroup. In the TN-MBC subgroup, the number of risk factors (pT2-3, N1-3) was related to significant differences in overall survival (P = .001) and recurrence-free survival (P < .001). CONCLUSION: The MBCpatients had a higher rate of TN, poorer differentiation, and a higher recurrence rate than did the IDC patients. Considering the unique characteristics and failure patterns, it is necessary to modify the current management guidelines for MBC.
Authors: Aron Gortman; Noel J Aherne; Justin Westhuyzen; Julan V Amalaseelan; Patrick M Dwyer; Matthew Hoffmann; Andrew T Last; Thomas P Shakespeare Journal: Mol Clin Oncol Date: 2021-07-01
Authors: Yongfeng Li; Meng Chen; Barbara Pardini; Mihnea P Dragomir; Anthony Lucci; George A Calin Journal: J Transl Med Date: 2019-09-23 Impact factor: 5.531
Authors: Brittany L Murphy; Robert T Fazzio; Tanya L Hoskin; Katrina N Glazebrook; Michael G Keeney; Elizabeth B Habermann; Tina J Hieken Journal: Gland Surg Date: 2018-04